Edition:
United Kingdom

Ritter Pharmaceuticals Inc (RTTR.OQ)

RTTR.OQ on NASDAQ Stock Exchange Capital Market

0.30USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
196,265
52-wk High
$3.75
52-wk Low
$0.28

Chart for

About

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and... (more)

Overall

Beta: --
Market Cap(Mil.): $5.57
Shares Outstanding(Mil.): 14.76
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-‍sabby Management reports 9.94 pct passive stakee in Ritter Pharmaceuticals

* ‍sabby Management, LLC​ reports 9.94 percent passive stakee in Ritter Pharmaceuticals Inc as of September 29 - sec filing Source text : http://bit.ly/2yWkm3T Further company coverage:

03 Oct 2017

BRIEF-RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE

* RITTER PHARMACEUTICALS, INC. RAISES $23 MILLION TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE

03 Oct 2017

BRIEF-Ritter Pharmaceuticals Inc prices $23,000,000 public offering

* Ritter Pharmaceuticals, Inc. prices $23,000,000 public offering

29 Sep 2017

BRIEF-Ritter Pharma announces Phase 3 plans after end of Phase 2 meeting with FDA on RP-G28

* Ritter Pharmaceuticals announces Phase 3 plans after its end of Phase 2 meeting with FDA on RP-G28 for lactose intolerance

18 Aug 2017

BRIEF-Ritter Pharmaceuticals reports further analysis from its phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms

* Ritter Pharmaceuticals reports further analysis from its phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms

03 Aug 2017

BRIEF-Ritter pharmaceuticals files for offering of up to $10 mln ‍​

* Ritter Pharmaceuticals files for offering of up to $10 million of class a units consisting of stock and warrants and class b units consisting of preferred stock & warrants ‍​ Source text (http://bit.ly/2skn9QC) Further company coverage:

03 Jul 2017

Earnings vs. Estimates